While BTK inhibitors have shown efficacy in subsets of ABC-DLBCL [38], their activity as single agents is frequently limited by the emergence of adaptive resistance and incomplete suppression of tumor survival programs. The gene discussed is BTK; the disease is diffuse large B-cell lymphoma.